Voyager Therapeutics, Inc.
Lead Plaintiff Deadline: 03/23/2021
SUMMARY OF CASE:
A securities class action has been filed against Voyager Therapeutics, Inc. (VYGR) on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Voyager securities between June 1, 2017 through November 9, 2020. This case has been filed in the USDC – E.D.N.Y.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleadingstatements regarding the Company’s business, operational and compliance policies. Specifically,Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s VY-HTT01 IND submission to the FDA lacked key information regarding certain chemistry, manufacturing and controls (“CMC”) matters, including, inter alia, drug-device
compatibility and drug substance and product characterization; (ii) the Company’s IND submission for VY-HTT01 was therefore deficient; (iii) the Company had thus materially overstated the likelihood of FDA approval for VY-HTT01 based on the IND submission; and (iv)as a result, the Company’s public statements were materially false and misleading at all relevant times.